Table 1 Demographics and baseline characteristics.

From: Efficacy and safety of pioglitazone versus dapagliflozin as an add-on to metformin and alogliptin combination therapy: the EPIDOTE study

Characteristic

Pioglitazone (n = 64)

Dapagliflozin (n = 67)

p value

Age, yr

59.2 ± 9.0

57.8 ± 9.5

0.446

Male, n (%)

36 (56.3)

29 (43.3)

0.138

Body weight, kg

69.8 ± 12.4

67.0 ± 10.6

0.190

BMI, kg/m2

26.0 ± 3.9

25.5 ± 2.7

0.858

HbA1c, %

7.9 ± 0.9

7.7 ± 0.7

0.528

FPG, mg/dL

156.6 ± 33.9

151.3 ± 34.3

0.201

HOMA-IR

4.2 ± 3.7

3.7 ± 3.3

0.315

HOMA-β

42.6 ± 29.4

41.4 ± 27.8

0.718

Total cholesterol, mg/dL

145.9 ± 25.9

150.9 ± 27.9

0.290

LDL-C, mg/dL

77.5 ± 23.2

86.2 ± 26.2

0.047

HDL-C, mg/dL

48.6 ± 13.8

46.9 ± 10.3

0.881

Triglyceride, mg/dL

166.0 ± 122.8

144.3 ± 59.6

0.767

eGFR, mL/min/1.73m2

103.5 ± 25.1

101.9 ± 21.8

0.723

  1. Data are expressed as mean ± standard deviation, or number (%).
  2. BMI body mass index; eGFR estimated glomerular filtration rate; FPG fasting plasma glucose; HbA1c glycated hemoglobin; HDL-C high-density lipoprotein cholesterol; HOMA-IR homeostasis model assessment of insulin resistance; HOMA-β homeostasis model assessment of β-cell function; LDL-C low-density lipoprotein cholesterol.
Back to article page